Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.

Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1027-1037.

View in: PubMed

subject areas

Aged, 80 and over
Aortic Valve Stenosis
Atrial Fibrillation
Cause of Death
Comorbidity
Europe
Female
Follow-Up Studies
Humans
Male
Postoperative Complications
Retrospective Studies
Risk Factors
Survival Rate
Time Factors
Transcatheter Aortic Valve Replacement
United States

authors with profiles

Usman Baber